Significantly greater antioxidant anticancer activities of 2,3-dehydrosilybin than silybin

Biochimica et Biophysica Acta - General Subjects

Volumn 1780, Issue 5, 2008, Pages 837-847

  Huber, Axel ^a   Thongphasuk, Piyanut ^b   Erben, Gerhard ^c   Lehmann, Wolf Dieter ^c   Tuma, Sabine ^a   Stremmel, Wolfgang ^a   Chamulitrat, Walee ^a  

^a Department of Internal Medicine IV ^*  (Germany)

^b RANGSIT UNIVERSITY   (Thailand)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antioxidant; Apoptosis; Cytoprotection; Flavonoid; Invasion; Liver injury; MMP 9; Reactive oxygen species; Transformed cell

Indexed keywords

2,3 DEHYDROSILYBIN; CISPLATIN; DOXORUBICIN; GALACTOSAMINE; GELATINASE A; GELATINASE B; GLUCOSE; GLUCOSE OXIDASE; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; SILIBININ; SILYMARIN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER INVASION; CELL PROTECTION; CELL STRAIN HEPG2; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIVER DISEASE; LIVER INJURY; MALE; METASTASIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GALACTOSAMINE; HEPATOCYTES; HUMANS; HYDROGEN PEROXIDE; KERATINOCYTES; LIVER DISEASES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; REACTIVE OXYGEN SPECIES; SILYMARIN;

EID: 45049088258     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2007.12.012     Document Type: Article

References (43)

1. Neuhouser M.L. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr. Cancer 50 (2004) 1-7
2. Aggarwal B.B., Kumar A., and Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23 (2003) 363-398
3. Shapiro G.I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res. 10 (2004) 4270s-4275s
4. Singh R.P., and Agarwal R. Prostate cancer prevention by silibinin. Curr. Cancer Drug Targets 4 (2004) 1-11
5. Gallo D., Giacomelli S., Ferlini C., Raspaglio G., Apollonio P., Prislei S., Riva A., Morazzoni P., Bombardelli E., and Scambia G. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. Eur. J. Cancer 39 (2003) 2403-2410
6. Wagner H., Horhammer L., and Seitz S. Chemical evaluation of a silymarin-containing flavonoid concentrate from Silybum marianum (L.) Ga. Arzneimittelforschung 18 (1968) 696-698
7. Wellington K., and Jarwis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. Bio. Drugs 15 (2001) 465-489
8. Gyorgy I., Antus S., Blazovics A., and Foldiak G. Substituent effects in the free radical reactions of silybin: radiation-induced oxidation of the flavonoid at neutral pH. Int. J. Radiat. Biol. 61 (1992) 603-609
9. Buettner G.R. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 300 (1993) 535-543
10. Davis-Searles P.R., Nakanishi Y., Kim N.C., Graf T.N., Oberlies N.H., Wani M.C., Wall M.E., Agarwal R., and Kroll D.J. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res. 65 (2005) 4448-4457
11. Kurkin V.A., Zapesoc G.G., Volotsuev A.V., Avdnd E.V., and Pimenov K.S. Flavolignans of Silybum marianum. Chem. Nat. Comp. 37 (2001) 315-317
12. Gazak R., Svobodova A., Psotova J., Sedmera P., Prikrylova V., Walterova V., and Kren V. Oxidised derivatives of silybin and their antiradical and antioxidant activity. Bioorg. Med. Chem. 12 (2004) 5677-5687
13. Dzubak P., Hajduch M., Gazak R., Svobodova A., Psotova J., Walterova D., Sedmera P., and Kren V. New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. Bioorg. Med. Chem. 14 (2006) 3793-3810
14. Chamulitrat W., Schmidt R., Chunglok W., Kohl A., and Tomakidi P. Epithelium and fibroblast-like phenotypes derived from HPV16 E6/E7-immortalized human gingival keratinocytes following chronic ethanol treatment. Eur. J. Cell Biol. 82 (2003) 313-322
15. Mueller S., Riedel H.D., and Stremmel W. Determination of catalase activity at physiological hydrogen peroxide concentrations. Anal. Biochem. 245 (1997) 55-60
16. Whiteman M., Rose P., Siau J.S., Cheung N.S., Tan G.S., Halliwell B., and Armstrong J.S. Free Rad. Biol. Med. 38 (2005) 1571-1584
17. Bai J., Rodriguez A.M., Melendez J.A., and Cederbaum A.I. Overexpression of catalase in cytosolic or mitochondrial compartment protects HepG2 cells against oxidative injury. J. Biol. Chem. 274 (1999) 26217-26224
18. Li Y., Zhu H., Kuppusamy P., Roubaud V., Zweier J.L., and Trush M.A. Validation of lucigenin (bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J. Biol. Chem. 273 (1998) 2015-2023
19. 2 exposure. Lab. Invest. 77 (1997) 533-539
20. Waas E.T., Wobbes T., Lomme R.M., DeGroot J., Ruers T., and Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br. J. Surg. 90 (2003) 1556-1564
21. Ogata Y., Enghild J.J., and Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J. Biol. Chem. 267 (1992) 3581-3584
22. Mori K., Shibanuma M., and Nose K. Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res. 64 (2004) 7464-7472
23. Varghese L., Agarwal C., Tyagi A., Singh R.P., and Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clin. Cancer Res. 11 (2005) 8441-8448
24. Caro A.A., and Cederbaum A.I. Synergistic toxicity of iron and arachidonic acid in HepG2 cells overexpressing CYP2E1. Mol. Pharmacol. 60 (2001) 742-752
25. Mira L., Silva M., and Manso C.F. Scavenging of reactive oxygen species by silibinin dehemisuccinate. Biochem. Pharmacol. 48 (1994) 753-759
26. Willaims R.J., Spencer J.P., and Rice-Evans C. Flavonoids: antioxidants or signalling molecules?. Free Radic. Biol. Med 36 (2004) 838-849
27. Varga Z., Seres I., Nagy E., Ujhelyi L., Balla G., and Antus S. Structure prerequisite for antioxidant activity of silybin in different biochemical systems in vitro. Phytomedicine 13 (2006) 85-93
28. Priyadarsini K.I., Guha S.N., and Rao M.N. Physico-chemical properties and antioxidant activities of methoxy phenols. Free Radic. Biol. Med. 24 (1998) 933-941
29. Borsari M., Gabbi C., Ghelfi F., Grandi R., Saladini M., Severi S., and Borella F. Silybin, a new iron-chelating agent. J. Inorg Biochem. 85 (2001) 123-129
30. Westermarck J., and Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13 (1999) 781-792
31. Chamulitrat W., Schmidt R., Chunglok W., Tomakidi P., Kawahara T., and Rokutan K. Association of gp91phox homolog Nox1 with anchorage-independent growth and MAP kinase-activation of transformed human keratinocytes. Oncogene 22 (2003) 6045-6054
32. Spallarossa F., Altieri P., Garibaldi S., Ghigliotti G., Barisione C., Manca V., Fabbi P., Ballestrero A., Brunelli C., and Barsotti A. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: the role of MAP kinases and NAD(P)H oxidase. Cardiovasc. Res. 69 (2006) 736-745
33. Nova D., Le Griel C., Holvoet S., Gentilhomme E., Vincent C., Staquet M.J., Schmitt D., and Serres M. Comparative studies on the secretion and activation of MMPs in two reconstructed human skin models using HaCaT- and HaCaT-ras-transfected cell lines. Clin. Exp. Metastasis 20 (2003) 675-683.
34. Brenneisen P., Sies H., and Scharffetter-Kochanek K. Ultraviolet-B irradiation and matrix metalloproteinases: from induction via signaling to initial events. Ann. NY. Acad. Sci. 973 (2002) 31-43
35. Bachmeier B.E., and Nerlich A.G. Immunohistochemical pattern of cytokeratins and MMPs in human keratinocyte cell lines of different biological behaviour. Int. J. Oncol. 20 3 (2002) 495-499
36. Singh R.P., Dhanalakshmi S., Agarwal C., and Agarwal R. Prostate cancer prevention by silibinin. Oncogene 24 (2005) 1188-1202
37. Pezzato E., Sartor L., Dell'Aica I., Dittadi R., Gion M., Belluco C., Lise M., and Garbisa S. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int. J. Cancer 112 (2004) 787-792
38. Chen H.W., Yu S.L., Chen J.J., Li H.N., Lin Y.C., Yao P.L., Chou H.Y., Chien C.T., Chen W.J., Lee Y.T., and Yang P.C. Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Mol. Pharmacol. 65 (2004) 99-110
39. Charvat S., Chignol M.C., Souchier C., Le Griel C., Schmitt D., and Serres M. Cell migration and MMP-9 secretion are increased by epidermal growth factor in HaCaT-ras transfected cells. Exp. Dermatol. 7 (1998) 184-190
40. Atsumi T., Murakami Y., Shibuya K., Tonosaki K., and Fujiisawa S. Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression, by curcumin and its analog, alpha-diisoeugenol. Anticancer Res. 25 (2005) 4029-4036
41. Hardcastle I.R., Golding B.T., and Griffin R.J. Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 325-348
42. Trompier D., Baubichon-Cortay H., Chang X.B., Maitrejean M., Barron D., Riordon J.R., and Di Pietro A. Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cell Mol. Life Sci. 60 (2003) 2164-2177
43. Son Y.O., Lee K.Y., Kook S.H., Lee J.C., Kim J.G., Jeon Y.M., and Jang Y.S. Selective effects of quercetin on the cell growth and antioxidant defense system in normal versus transformed mouse hepatic cell lines. Eur. J. Pharmacol. 50 (2004) 195-204